GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Oseltamivir

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

CAPD threshold differs between the mirror and official label

The mirror CAPD row prints below 10 mL/min; the dated official label includes 10 or below. Treatment and prophylaxis schedules also differ.

Before applying: Preserve the discrepancy; use the exact population, modality and indication. Do not transfer CAPD guidance to automated PD or CRRT.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

TAMIFLU - official adult renal and dialysis regimens

Product / population
TAMIFLU capsules/suspension; adult renal Table 2 only.
Renal measure
CrCl (mL/min)
Before using this finding

Treatment, prophylaxis and dialysis schedules differ. Confirm duration and modality.

Renal guidance and important limits

Adult oral regimens; treatment lasts 5 days unless the dialysis row specifies a single dose.

CrCl / modalityTreatmentProphylaxis
Above 30 through 60 mL/min30 mg twice daily30 mg daily
Above 10 through 30 mL/min30 mg daily30 mg every other day
HD, CrCl 10 or below30 mg immediately then after every session; duration no more than 5 days30 mg immediately then after alternate sessions
CAPD, CrCl 10 or belowSingle 30 mg dose immediately30 mg immediately then weekly
ESRD without dialysisNot recommendedNot recommended

Prophylaxis continues for the source-defined exposure/outbreak duration, not automatically 5 days. CAPD evidence is not an automated-PD or CRRT schedule. The older official label's CAPD boundary includes exactly 10, unlike the selected mirror. Adult renal schedules do not establish pediatric renal doses.

Source revision: 8/2019 (dated label) | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee3c9555-60f2-4f82-a760-11983c86e97b

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

TAMIFLU - official adult renal and dialysis regimens

Authored v6.1; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

GlobalRPh RX List - TAMIFLU

Authored v6.1; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

TAMIFLU - official adult renal and dialysis regimens

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Treatment, prophylaxis and dialysis schedules differ. Confirm duration and modality.

Dialysis evidence: A regimen is reported in selected content

TAMIFLU capsules/suspension; adult renal Table 2 only.

Renal method: CrCl (mL/min)
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - TAMIFLU

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check treatment versus prevention and the exact dialysis modality; the CAPD threshold differs from the official label.

Dialysis evidence: A regimen is reported in selected content

TAMIFLU adult renal table; influenza treatment and prophylaxis are distinct.

Renal method: Source-specific renal measure; see text
Retrieved: 2026-09-10

Read local renal resultOpen original reference
Professional guidance

UCSF - oseltamivir treatment versus prevention

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

CAPD threshold differs between the mirror and official label

The mirror CAPD row prints below 10 mL/min; the dated official label includes 10 or below. Treatment and prophylaxis schedules also differ.

How to use this: Preserve the discrepancy; use the exact population, modality and indication. Do not transfer CAPD guidance to automated PD or CRRT.

GlobalRPh RX List - TAMIFLUTAMIFLU - official adult renal and dialysis regimens

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeTAMIFLU - official adult renal and dialysis regimensGlobalRPh RX List - TAMIFLUUCSF - oseltamivir treatment versus prevention
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/oseltamivir/

Usual dosing

Influenza treatment: adults/adolescents at least 13 years, 75 mg twice daily for 5 days. Ages 1-12 years: weight-based twice-daily dosing for 5 days; the weight table is not reproduced on this source page. Age 2 weeks to under 1 year: 3 mg/kg twice daily for 5 days.

Prophylaxis: adults/adolescents, 75 mg daily for at least 10 days, or up to 6 weeks during a community outbreak. Ages 1-12: weight-based once daily for 10 days, or up to 6 weeks in an outbreak.

GRPH-oseltamivir-01 · Source section: Usual dosingRenal section finder

Adult renal treatment table

CrCl above 60-90 mL/min: 75 mg twice daily for 5 days.

Above 30-60: 30 mg twice daily for 5 days.

Above 10-30: 30 mg once daily for 5 days.

ESRD on HD, CrCl at or below 10: 30 mg after each HD cycle; treatment period no longer than 5 days. This assumes three sessions in 5 days. Treatment may begin immediately during the 48 hours between sessions; give the post-HD dose regardless of when the first dose was administered.

ESRD on CAPD: one 30 mg dose immediately after an exchange. Evidence is from CAPD, not every peritoneal-dialysis modality.

GRPH-oseltamivir-02 · Source section: Adult renal treatment tableRenal section finder

Adult renal prophylaxis table

CrCl above 60-90: 75 mg daily.

Above 30-60: 30 mg daily.

Above 10-30: 30 mg every other day.

ESRD on HD: 30 mg after alternate HD cycles; an initial dose can be given before dialysis begins.

ESRD on CAPD: 30 mg once weekly immediately after an exchange.

Use the usual prophylaxis duration. Capsules or suspension can provide 30 mg doses. Not recommended for ESRD without dialysis.

GRPH-oseltamivir-03 · Source section: Adult renal prophylaxis tableRenal section finder

Hemodialysis

Treatment and prophylaxis have different schedules; use their separate tables above.

GRPH-oseltamivir-04 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

TAMIFLU - official adult renal and dialysis regimens

Open original reference

Open / share this exact local source

National Library of Medicine / manufacturer labeling · TAMIFLU capsules/suspension; adult renal Table 2 only.

Renal method: CrCl (mL/min)
Source date: 8/2019 (dated label)
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Treatment, prophylaxis and dialysis schedules differ. Confirm duration and modality.

Dialysis evidence: A regimen is reported in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Adult oral regimens; treatment lasts 5 days unless the dialysis row specifies a single dose.

CrCl / modalityTreatmentProphylaxis
Above 30 through 60 mL/min30 mg twice daily30 mg daily
Above 10 through 30 mL/min30 mg daily30 mg every other day
HD, CrCl 10 or below30 mg immediately then after every session; duration no more than 5 days30 mg immediately then after alternate sessions
CAPD, CrCl 10 or belowSingle 30 mg dose immediately30 mg immediately then weekly
ESRD without dialysisNot recommendedNot recommended

Prophylaxis continues for the source-defined exposure/outbreak duration, not automatically 5 days. CAPD evidence is not an automated-PD or CRRT schedule. The older official label's CAPD boundary includes exactly 10, unlike the selected mirror. Adult renal schedules do not establish pediatric renal doses.

RDM61-official-oseltamivir-bf8fc38196-C1 · Source locator: 2.4 and Table 2

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee3c9555-60f2-4f82-a760-11983c86e97b
Retrieved
2026-09-10
Exact label title
TAMIFLU - official adult renal and dialysis regimens
DailyMed Set ID
ee3c9555-60f2-4f82-a760-11983c86e97b
Label revision
8/2019 (dated label)
Renal-function method
CrCl (mL/min)
Source date/version
8/2019 (dated label)
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
587ab322f0f253e629fa85de7cd8814a688df0f4ecbb8d754ba0ee5a083a393a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - TAMIFLU

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · TAMIFLU adult renal table; influenza treatment and prophylaxis are distinct.

Renal method: Source-specific renal measure; see text
Source date: Revision not established in selected retrieval
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Check treatment versus prevention and the exact dialysis modality; the CAPD threshold differs from the official label.

Dialysis evidence: A regimen is reported in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

The adult table distinguishes influenza treatment from prophylaxis. At CrCl above 30 through 60 mL/min, treatment is 30 mg twice daily for 5 days; prophylaxis is 30 mg daily. At above 10 through 30, treatment is 30 mg daily for 5 days; prophylaxis is 30 mg every other day. Hemodialysis treatment is 30 mg immediately then after every session, over no more than 5 days; prophylaxis uses alternate sessions after the initial dose. The CAPD row prints below 10, whereas the retrieved official label prints 10 or below. Do not silently reconcile that boundary. Adult schedules are not pediatric renal recommendations.

RDM61-rxlist-oseltamivir-76f7883d13-C1 · Source locator: Dosage and Administration: renal impairment; named precautions

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/tamiflu-drug/
Retrieved
2026-09-10
Renal-function method
Source-specific renal measure; see text
Source date/version
Revision not established in selected retrieval
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
c788b719ab156f3df36a4aff2954720179d970ccb63223796cf7a308e5d1ed9e
Separate professional-source layer

University and professional protocols

Professional

UCSF - oseltamivir treatment versus prevention

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Choose duration separately. No non-dialysis regimen below the displayed range is inferred.

Influenza treatment - oral
CrCl, mL/minSource-specific dose / instruction
>6075 mg twice daily
31-6030 mg twice daily
10-3030 mg daily
Influenza prevention - oral
CrCl, mL/minSource-specific dose / instruction
>6075 mg daily
31-6030 mg daily
10-3030 mg every other day
Dialysis guidance - separate source-specific schedules
Oseltamivir dialysis
Dialysis setting / indicationSource-specific schedule
IHD treatment30 mg initially and after HD
IHD prevention30 mg once weekly
Continuous HD treatment75 mg twice daily
Continuous HD prevention30 mg daily
Read the retained text before reformatting

CrCl >60 / 31-60 / 10-30 mL/min: influenza treatment uses 75 mg orally twice daily / 30 mg twice daily / 30 mg daily. Prevention uses 75 mg daily / 30 mg daily / 30 mg every other day.

Intermittent-HD treatment: 30 mg initially and after HD; prevention: 30 mg once weekly. Continuous-HD treatment: 75 mg twice daily; prevention: 30 mg daily. Course duration is selected separately. No non-dialysis dose below the listed clearance range is inferred.

RDM30-043-oseltamivir-1 · Source locator: UCSF - oseltamivir treatment versus prevention; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/oseltamivir
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
0ecf61f68c61d350792212142104e18aa41970d9baa2b2485818b44235505ede

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/oseltamivir/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
fac6eba181e2ab5d615bd0b0c975c9e2467a77ab7f625f059c49dbe3892c2708
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report